{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T03:54:51Z","timestamp":1781495691972,"version":"3.54.1"},"reference-count":35,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"USWM CT, LLC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Trabectedin is a standard-of-care chemotherapy for recurrent\/metastatic liposarcomas, including myxoid\/round cell liposarcoma (MRCLS). This pooled analysis was performed to evaluate trabectedin efficacy in MRCLS across multiple trials to establish a standard-of-care efficacy baseline. Methods: The Yale University Open Data Access (YODA) Project was queried for prospective trabectedin trials. Data on patients with unresectable, locally advanced\/metastatic MRCLS who received \u2265 1 trabectedin dose(s) (1.0\u20131.5 mg\/m2 administered as a 24-h continuous infusion every 3 weeks) were extracted from three trials: NCT00060944, NCT00210665, and NCT01343277. The primary outcome was the objective response rate as per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Secondary outcomes included disease control rate and overall survival, defined as the time from first trabectedin administration to death. Responses were assessed using RECIST by investigators in NCT01343277 and by independent review in NCT00060944. In NCT00210665, tumor assessment followed institutional standards, so only overall survival was analyzed. Results: Sixty-three patients were included (42 from NCT01343277, 13 from NCT00060944, 8 from NCT00210665): 32% were female, the median age was 50 years, and 79% were White. The objective response rate was 16.3% (8\/49) of patients (37 from NCT01343277, 12 from NCT00060944). The disease control rate was 77.6% (38\/49). Overall survival data were available for 63 patients: the median overall survival was 22.51 months (95% CI: 16.99\u201334.33). Conclusions: This analysis represents one of the largest pooled populations to date of patients with advanced MRCLS treated with trabectedin in prospective clinical trials to be reported. Whilst limited by typical factors affecting pooled analyses, including cross-study heterogeneity, nevertheless the results estimate a trabectedin efficacy baseline against which to inform other therapies for MRCLS.<\/jats:p>","DOI":"10.3390\/cancers18121921","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T09:49:51Z","timestamp":1781257791000},"page":"1921","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pooled Analysis of Trabectedin Efficacy in Myxoid\/Round Cell Liposarcoma from Three Prospective Clinical Trials"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8888-4482","authenticated-orcid":false,"given":"Michael Jason","family":"Nathenson","sequence":"first","affiliation":[{"name":"US World Meds, Louisville, KY 40241, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Hoch","sequence":"additional","affiliation":[{"name":"Adaptimmune, Oxfordshire OX14 4SB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Ireland","sequence":"additional","affiliation":[{"name":"Adaptimmune, Oxfordshire OX14 4SB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"O\u2019Nians Michalowicz","sequence":"additional","affiliation":[{"name":"US World Meds, Louisville, KY 40241, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Williams","sequence":"additional","affiliation":[{"name":"Verismo Therapeutics, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0146-7732","authenticated-orcid":false,"given":"Neeta","family":"Somaiah","sequence":"additional","affiliation":[{"name":"Department of Sarcoma Medical Oncology, UT MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","article-title":"Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial","volume":"34","author":"Demetri","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_2","unstructured":"FDA (2024, June 17). YONDELIS (Trabectedin) Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/207953s005lbl.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s11864-023-01057-4","article-title":"Myxoid Liposarcomas: Systemic Treatment Options","volume":"24","author":"Nassif","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Bock, S., Hoffmann, D.G., Jiang, Y., Chen, H., and Il\u2019yasova, D. (2020). Increasing Incidence of Liposarcoma: A Population-Based Study of National Surveillance Databases, 2001\u20132016. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17082710"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Amadeo, B., Penel, N., Coindre, J.M., Ray-Coquard, I., Ligier, K., Delafosse, P., Bouvier, A.M., Plouvier, S., Gallet, J., and Lacourt, A. (2020). Incidence and time trends of sarcoma (2000\u20132013): Results from the French network of cancer registries (FRANCIM). BMC Cancer, 20.","DOI":"10.1186\/s12885-020-6683-0"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"100215","DOI":"10.1016\/j.eclinm.2019.11.008","article-title":"Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors","volume":"17","author":"Callegaro","year":"2019","journal-title":"EClinicalMedicine"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1002\/cam4.3039","article-title":"Clinical outcomes of patients with advanced synovial sarcoma or myxoid\/round cell liposarcoma treated at major cancer centers in the United States","volume":"9","author":"Pollack","year":"2020","journal-title":"Cancer Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2437850","DOI":"10.1155\/2020\/2437850","article-title":"Time Trends and Prognostic Factors for Overall Survival in Myxoid Liposarcomas: A Population-Based Study","volume":"2020","author":"Lansu","year":"2020","journal-title":"Sarcoma"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"538085","DOI":"10.1155\/2011\/538085","article-title":"Prognostic factors and metastatic patterns in primary myxoid\/round-cell liposarcoma","volume":"2011","author":"Haniball","year":"2011","journal-title":"Sarcoma"},{"key":"ref_10","unstructured":"Fletcher, C.D.M., Bridge, J.A., Hogendoorn, P.C.W., and Mertens, F. (2013). WHO Classification of Tumours of Soft Tissue and Bone, International Agency for Research on Cancer (IARC). [4th ed.]."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1158\/1535-7163.MCT-10-0263","article-title":"A review of trabectedin (ET-743): A unique mechanism of action","volume":"9","author":"Galmarini","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1038\/onc.2013.462","article-title":"Mode of action of trabectedin in myxoid liposarcomas","volume":"33","author":"Frapolli","year":"2014","journal-title":"Oncogene"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s13046-024-03228-z","article-title":"Mechanism of efficacy of trabectedin against myxoid liposarcoma entails detachment of the FUS-DDIT3 transcription factor from its DNA binding sites","volume":"43","author":"Craparotta","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Allavena, P., Belgiovine, C., Digifico, E., Frapolli, R., and D\u2019Incalci, M. (2022). Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.851790"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.2217\/fon-2022-0348","article-title":"Meta-analysis of pazopanib and trabectedin effectiveness in previously treated metastatic synovial sarcoma (second-line setting and beyond)","volume":"18","author":"Carroll","year":"2022","journal-title":"Future Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1016\/j.ejca.2012.05.012","article-title":"A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas","volume":"48","author":"Cresta","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1634\/theoncologist.2016-0064","article-title":"Efficacy of Trabectedin in Patients with Advanced Translocation-Related Sarcomas: Pooled Analysis of Two Phase II Studies","volume":"22","author":"Takahashi","year":"2017","journal-title":"Oncologist"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/bjc.2013.524","article-title":"Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: A retrospective pooled analysis of five phase II trials","volume":"109","author":"Cesne","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1470-2045(07)70175-4","article-title":"Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: A retrospective study","volume":"8","author":"Grosso","year":"2007","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/ijc.34309","article-title":"Trabectedin use in soft-tissue sarcoma patients in a real-world setting: Data from an Italian national drug-access registry","volume":"152","author":"Vincenzi","year":"2023","journal-title":"Int. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Ohmoto, A., Nakano, K., Fukuda, N., Wang, X., Urasaki, T., Hayashi, N., Suto, H., Udagawa, S., Oki, R., and Sato, Y. (2023). Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective study. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0280508"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/annonc\/mdp004","article-title":"Trabectedin in myxoid liposarcomas (MLS): A long-term analysis of a single-institution series","volume":"20","author":"Grosso","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ctrv.2018.11.003","article-title":"A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma","volume":"72","author":"Assi","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/annonc\/mdr265","article-title":"Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma","volume":"23","author":"Gronchi","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1200\/JCO.19.03289","article-title":"Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups","volume":"38","author":"Gronchi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S1470-2045(17)30334-0","article-title":"Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): An international, open-label, randomised, controlled, phase 3, multicentre trial","volume":"18","author":"Gronchi","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1200\/JCO.23.00908","article-title":"Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG)","volume":"42","author":"Gronchi","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: A randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2008.21.0088","article-title":"Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: Results of a randomized phase II study of two different schedules","volume":"27","author":"Demetri","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The Use of Confidence or Fiducial Limits Illustrated in the Case of the Binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric Estimation from Incomplete Observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","article-title":"A Confidence Interval for the Median Survival Time","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Schoffski","year":"2016","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2020.1707","article-title":"Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial","volume":"323","author":"Tap","year":"2020","journal-title":"JAMA"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/12\/1921\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T03:37:48Z","timestamp":1781494668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/12\/1921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":35,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["cancers18121921"],"URL":"https:\/\/doi.org\/10.3390\/cancers18121921","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]}}}